Jiaming Wang

Jiaming Wang

Auto-generated profile, based on publicly available information

Jiaming Wang

Department of Neurosurgery, First Affiliated Hospital of Xinjiang Medical University, Ürümqi, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2020 in Blood
Verified
Journal Article
Open access
PDF file
YYYingying Yu
Yingying Yu
LJLi Jiang
Li Jiang
HWHao Wang
Hao Wang
ZSZhe Shen
Zhe Shen
QCQi Cheng
Qi Cheng
Fudi WangFudi Wang
Fudi Wang
Although the serum-abundant metal-binding protein transferrin (encoded by the Trf gene) is synthesized primarily in the liver, its function in the liver is largely unknown. Here, we generated hepatocyte-specific Trf knockout mice (Trf-LKO), which are viable and fertile but have impaired erythropoiesis and altered iron metabolism. Moreover, feeding Trf-LKO mice a high-iron diet increased their susceptibility to developing ferroptosis-induced liver fibrosis. Importantly, we found that treating Trf-LKO mice with the ferroptosis inhibitor ferrostatin-1 potently rescued liver fibrosis induced by either high dietary iron or carbon tetrachloride (CCl4) injections. In addition, deleting hepatic Slc39a14 expression in Trf-LKO mice significantly reduced hepatic iron accumulation, thereby reducing ferroptosis-mediated liver fibrosis induced by either a high-iron diet or CCl4 injections. Finally, we found that patients with liver cirrhosis have significantly lower levels of serum transferrin and hepatic transferrin, as well as higher levels of hepatic iron and lipid peroxidation, compared with healthy control subjects. Taken together, these data indicate that hepatic transferrin plays a protective role in maintaining liver function, providing a possible therapeutic target for preventing ferroptosis-induced liver fibrosis.

25 April 2021 in Blood
Verified
Journal Article
Open access
PDF file
LJLi Jiang
Li Jiang
JWJiaming Wang
Jiaming Wang
KWKai Wang
Kai Wang
HWHao Wang
Hao Wang
QWQian Wu
Qian Wu
Fudi WangFudi Wang
Fudi Wang
Ferroportin (FPN), the body’s sole iron exporter, is essential for maintaining systemic iron homeostasis. In response to either increased iron or inflammation, hepatocyte-secreted hepcidin binds to FPN, inducing its internalization and subsequent degradation. However, the E3 ubiquitin ligase that underlies FPN degradation has not been identified. Here, we report the identification and characterization of a novel mechanism involving the RNF217-mediated degradation of FPN. A combination of 2 different E3 screens revealed that the Rnf217 gene is a target of Tet1, mediating the ubiquitination and subsequent degradation of FPN. Interestingly, loss of Tet1 expression causes an accumulation of FPN and an impaired response to iron overload, manifested by increased iron accumulation in the liver together with decreased iron in the spleen and duodenum. Moreover, we found that the degradation and ubiquitination of FPN could be attenuated by mutating RNF217. Finally, using 2 conditional knockout mouse lines, we found that knocking out Rnf217 in macrophages increases splenic iron export by stabilizing FPN, whereas knocking out Rnf217 in intestinal cells appears to increase iron absorption. These findings suggest that the Tet1-RNF217-FPN axis regulates iron homeostasis, revealing new therapeutic targets for FPN-related diseases.

17 December 2021 in Science Advances
Verified
Journal Article
Open access
HLHuirong Lin
Huirong Lin
YZYu Zhou
Yu Zhou
JWJiaming Wang
Jiaming Wang
HWHuimeng Wang
Huimeng Wang
TYTianhong Yao
Tianhong Yao
Gang LiuGang Liu
Gang Liu
Indocyanine green was repurposed as iron theranostics for simultaneous detection and treatment of iron-overload disorders.

1 June 2021 in Lung Cancer
Verified
Journal Article
Closed access
CZChen-Chen Zhang
Chen-Chen Zhang
RHRun-Ping Hou
Run-Ping Hou
WXWu-Yan Xia
Wu-Yan Xia
WZWan-Qin Zeng
Wan-Qin Zeng
JLJun Liu
Jun Liu
XFXiaolong Fu
Xiaolong Fu

6 May 2022 in Frontiers in Human Neuroscience
Verified
Journal Article
Open access
JWJiaming Wang
Jiaming Wang
YTYu Tian
Yu Tian
Xin ShiXin Shi
Xin Shi
ZFZhaohai Feng
Zhaohai Feng
LJLei Jiang
Lei Jiang
YHYujun Hao
Yujun Hao
Background: The past four decades have seen the growing use of tissue or cell transplants in Parkinson’s disease (PD) treatment. Parkinson’s cell therapy is a promising new treatment; however, efficacy of cell transplantation for Parkinson’s disease are entirely unclear.Objective: To conduct a meta-analysis and a systematic review of the efficacy of cell therapy in patients with PD.Methods: A systematic literature review and meta-analysis of 10 studies were performed to assess the efficacy of cell therapy in Parkinson’s patients. To achieve this, we compared the change in Unified Parkinson’s Disease Rating Scale (UPDRS) II and III scale scores to baseline and assessed the incidence of transplant-related adverse events. The MINORS score and the I2 index were applied to evaluate the quality of studies between-study heterogeneity, respectively.Results: The literature search yielded 10 articles (n = 120). The improvement in motor function based on the UPDRSIII assessment was −14.044 (95% CI: −20.761, −7.327) (p < 0.001), whereas improvement in daily living ability based on the UPDRSII assessment was −5.661 (95% CI: −7.632, −3.689) (p < 0.001).Conclusion: The present findings demonstrate important clues on the therapeutic effect of cell therapy in alleviating motor impairment and daily living ability in PD patients.